Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - chlormethine hydrochloride, quantity: 0.2 mg/g (equivalent: chlormethine, qty 0.16 mg/g) - gel - excipient ingredients: butylated hydroxytoluene; disodium edetate; diethylene glycol monoethyl ether; isopropyl alcohol; hyprolose; lactic acid; propylene glycol; glycerol; menthol; sodium chloride - ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous t-cell lymphoma (mf-type ctcl) in adult patients.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 0.1mg (drug substance stabilished in butylhydroxytoluene);  ;   - dispersible tablet - 0.1 mg - active: everolimus 0.1mg (drug substance stabilished in butylhydroxytoluene)     excipient: butylated hydroxytoluene colloidal silicon dioxide crospovidone hypromellose lactose lactose monohydrate magnesium stearate - certican is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving an allogenic renal or cardiac transplant and in adult patients receiving an allogenic hepatic transplant (see precautions).

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 0.25mg (drug substance stabilised with butylhydroxytoluene);  ;   - dispersible tablet - 0.25 mg - active: everolimus 0.25mg (drug substance stabilised with butylhydroxytoluene)     excipient: butylated hydroxytoluene colloidal silicon dioxide crospovidone hypromellose lactose lactose monohydrate magnesium stearate - certican is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving an allogenic renal or cardiac transplant and in adult patients receiving an allogenic hepatic transplant (see precautions).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: quinoline yellow; purified talc; polyethylene oxide; cochineal; microcrystalline cellulose; magnesium stearate; hyprolose; butylated hydroxytoluene; macrogol 400; titanium dioxide; iron oxide black; hypromellose; colloidal anhydrous silica - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

lawley pharmaceuticals pty ltd - testosterone, quantity: 10 mg/ml - cream - excipient ingredients: almond oil; butylated hydroxytoluene; carbomer 940; cetomacrogol 1000; cetostearyl alcohol; citric acid; dl-alpha-tocopheryl acetate; trolamine; purified water; phenoxyethanol; propyl hydroxybenzoate; ethyl hydroxybenzoate; isobutyl hydroxybenzoate; butyl hydroxybenzoate; methyl hydroxybenzoate - androfeme 1 is indicated for the treatment of hypoactive sexual desire dysfunction (hsdd) in postmenopausal women. therapeutic intervention with androfeme 1 should only be initiated in women following failure of appropriate education and correction of modifiable biopsychosocial factors (which may include neuroendocrine imbalance, physical ill health or disease, interpersonal difficulties, psychological distress or specific cultural or religious beliefs), according to the international society for the study of women?s sexual health (isswsh) process of care (see figure 1).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fluorouracil, quantity: 40 mg/g - cream - excipient ingredients: stearoyl macrogolglycerides; butylated hydroxytoluene; cetyl alcohol; citric acid; glycerol; isopropyl myristate; methyl hydroxybenzoate; propyl hydroxybenzoate; purified water; arachis oil; sodium hydroxide; stearic acid; stearyl alcohol; methyl gluceth-10 - tolak 4% once daily is indicated for the topical treatment of actinic keratosis (ak) of the face, ears, and/or scalp in adults.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: quinoline yellow; purified talc; polyethylene oxide; cochineal; microcrystalline cellulose; magnesium stearate; hyprolose; butylated hydroxytoluene; macrogol 400; titanium dioxide; iron oxide black; hypromellose; colloidal anhydrous silica - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: purified water; hypromellose phthalate; tartaric acid; butylated hydroxytoluene; hyprolose; microcrystalline cellulose; dichloromethane; purified talc; isopropyl alcohol; macrogol 600; citric acid monohydrate; ethanol; povidone; titanium dioxide; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; macrogol 8000; hypromellose; sunset yellow fcf - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: purified water; hypromellose phthalate; hyprolose; dichloromethane; tartaric acid; ethanol; butylated hydroxytoluene; povidone; purified talc; citric acid monohydrate; isopropyl alcohol; microcrystalline cellulose; macrogol 600; titanium dioxide; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; hypromellose; sunset yellow fcf; macrogol 8000 - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: citric acid monohydrate; butylated hydroxytoluene; dichloromethane; microcrystalline cellulose; ethanol; povidone; tartaric acid; macrogol 600; purified talc; isopropyl alcohol; hyprolose; hypromellose phthalate; purified water; titanium dioxide; hypromellose; sunset yellow fcf; macrogol 8000; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.